<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Erwin Mulyawan</style></author><author><style face="normal" font="default" size="100%">Clarissa Jasmine Aurelia</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and Safety of Propofol Drip versus Thiopental with Midazolam in Children Undergoing Magnetic Resonance Imaging Studies</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Children</style></keyword><keyword><style  face="normal" font="default" size="100%">MRI</style></keyword><keyword><style  face="normal" font="default" size="100%">Propofol</style></keyword><keyword><style  face="normal" font="default" size="100%">Thiopental</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2025</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">289-292</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Pediatrics often require sedatives during Magnetic Resonance Imaging (MRI) due to its lengthy, loud, and restricted space. This study aims to compare efficacy and safety of propofol drip and thiopental with midazolam for children undergoing MRI. &lt;strong&gt;Methods: &lt;/strong&gt;This randomised double-blinded cohort study was conducted in patients aged 3-10 years old with ASA status I-II scheduled for outpatient MRI. Exclusion criteria include airway abnormalities, allergic reactions to anesthetic agents, renal, hepatic, and seizure history, or was pre-medicated. Patients were administered propofol (group PF) or midazolam with thiopental (group TH). Data including patient history, physiologic parameters, duration, recovery, discharge time, and adverse events were recorded. Data was statistically analysed using Chi Square and Student T-test. &lt;strong&gt;Results: &lt;/strong&gt;A total of 34 patients were included in this study, 18 in PF and 16 TH. Sedation onset, recovery time, and mean discharge was significantly shorter in PF versus TH (6 vs 10 mins (p &amp;lt;0.0001); 8 vs 13 mins (p &amp;lt;0.0001), and 69 vs 89 mins (p &amp;lt;0.0001)). No significant differences in duration and physiologic parameters between both groups were found. No adverse events occurred in both groups. 6.25% of patients in group PF and 33.33% in group TH had inadequate sedation. &lt;strong&gt;Conclusion: &lt;/strong&gt;This study found PF has faster sedation onset and recovery time in comparison to TH for children undergoing MRI with no significant differences in physiologic parameters and adverse events. Further studies conducted on a larger population investigating efficacy and adverse events of alternative sedatives is recommended.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">289</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Erwin Mulyawan&lt;sup&gt;1*&lt;/sup&gt;, Clarissa Jasmine Aurelia&lt;sup&gt;2&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Anesthesiology and Intensive Care, Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, 15810, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, 15810, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Putu Virgina Angga Saraswati</style></author><author><style face="normal" font="default" size="100%">Mahrus Abdur Rahman</style></author><author><style face="normal" font="default" size="100%">Risky Vitria Prasetyo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of Magnesium Supplementation on the Carotid Intima Media Thickness in Children with Chronic Kidney Disease and Hyperphosphatemia: A Double-blind Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Carotid Intima Media Thickness</style></keyword><keyword><style  face="normal" font="default" size="100%">Children</style></keyword><keyword><style  face="normal" font="default" size="100%">Chronic Kidney Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Hyperphosphatemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Magnesium</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">1056-1061</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Hyperphosphatemia has been emphasized to be a significant risk factor for vascular calcification in CKD patients. This study aims to investigate the effect of magnesium supplementation on the reduction of phosphate levels and carotid intima media thickness in children as predictor on vascular calcification with CKD and hyperphosphatemia, compared to a placebo.&lt;strong&gt; Methods:&lt;/strong&gt; A randomized, double-blind, placebo-controlled trial was conducted at Pediatric Ward and Outpatient Clinic of Pediatric Nephrology in our setting during October-March 2023. We compared oral magnesium supplementation (6 mg/kg body weight/day for two months) with a placebo in children with CKD and hyperphosphatemia (ages 1-18 years old). Patients who were on dialysis and had serum magnesium levels of &amp;lt;1.6 mg/dL and &amp;gt;2.4 mg/dL, and were allergic to magnesium supplementation were excluded. A paired T-test and the Wilcoxon signed-rank test were used for statistical analysis. &lt;strong&gt;Results:&lt;/strong&gt; We collected 25 children in the experimental group and 25 children in the placebo group. Phosphate levels were decreased in both the magnesium supplementation and placebo groups (6.1 ± 0.79 to 6.0 ± 0.63 mg/dL; p-value = 0.852 and 6.01 ± 0.55 to 5.8 ± 0.64 mg/dL; p-value=0.365). However, when compared between groups, the reductions were not significantly different (0.1 vs 0.21; p-value=0.935). A significant improvement was found in carotid intima media thickness in both groups (0.05±0.01 to 0.05±0.01; p-value=0.000 and 0.05±0.01 to 0.05±0.01; p-value=0.000), and the reductions were significantly different (0.01 vs 0.01; p-value=0.000). &lt;strong&gt;Conclusion: &lt;/strong&gt;Magnesium supplements have considerably lower phosphate levels and significantly reduced the thickness on carotid intima media in children with CKD and hyperphosphatemia.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">1056</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Putu Virgina Angga Saraswati&lt;sup&gt;1,2&lt;/sup&gt;, Mahrus Abdur Rahman&lt;sup&gt;1,2&lt;/sup&gt;, Risky Vitria Prasetyo&lt;sup&gt;1,2*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Child Health, Dr Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Child Health, Faculty of Medicine- Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muqiemuddin Salim</style></author><author><style face="normal" font="default" size="100%">I Ketut Alit Utamayasa</style></author><author><style face="normal" font="default" size="100%">Roedi Irawan</style></author><author><style face="normal" font="default" size="100%">Irwanto</style></author><author><style face="normal" font="default" size="100%">Azwin Mengindra Putera</style></author><author><style face="normal" font="default" size="100%">Meity Ardiana</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Effect of Cardiac Catheterization Intervention on The Nutritional Status of Children with Acyanotic Congenital Heart Disease</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acyanotic CHD</style></keyword><keyword><style  face="normal" font="default" size="100%">Children</style></keyword><keyword><style  face="normal" font="default" size="100%">Congenital heart disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Interventional cardiac catheterization.</style></keyword><keyword><style  face="normal" font="default" size="100%">Nutritional status</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">338-342</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Intervention is required since malnutrition in children with acyanotic congenital heart disease (CHD) will affect growth, development, and quality of life. Research on the impact of cardiac catheterization on the nutritional health of children with acyanotic CHD is limited, particularly in Indonesia. This study aims to analyze the effect of cardiac catheterization on the nutritional status of children with acyanotic CHD. &lt;strong&gt;Methods: &lt;/strong&gt;A cross-sectional study was conducted between January 2019 and December 2021. The participants of this study were children aged 1-60 months with acyanotic CHD who had undergone cardiac catheterization. We compare the nutritional status of participants in three observation stages, including pre-intervention of catheterization and the 3rd and 6th months post-cardiac catheterization. The parameters of nutritional status are determined according to the mean of Z-scores of weight-for-age (WAZ), length-for-age (LAZ), and weight-for-length (WLZ) of participants. &lt;strong&gt;Results: &lt;/strong&gt;A total of children with acyanotic CHD who underwent catheterization and 49 children were eligible participants. The mean age of children with acyanotic CHD patients who underwent catheterization was 31.51 months, and 89% of them were 1-5 years. Fifty-three percent of participants who underwent cardiac catheterization were male. The most common acyanotic CHD defects were the Patent Ductus Arteriosus (PDA) among 55.1% of participants. Significant differences were found in WAZ, LAZ, and WLZ in the measurement of three observation stages (p&amp;lt;0.05). &lt;strong&gt;Conclusion:&lt;/strong&gt; Interventional cardiac catheterization affects and enhances the nutritional status of children with acyanotic CHD and may be suggested as an initial therapy to further evaluate the disease.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">338</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Muqiemuddin Salim&lt;sup&gt;1&lt;/sup&gt;, I Ketut Alit Utamayasa&lt;sup&gt;1,*&lt;/sup&gt;, Roedi Irawan&lt;sup&gt;1&lt;/sup&gt;, Irwanto&lt;sup&gt;1&lt;/sup&gt;, Azwin Mengindra Putera&lt;sup&gt;1&lt;/sup&gt;, Meity Ardiana&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Child Health, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Cardiology and Vascular Medicine, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Glabela Christiana Pandango</style></author><author><style face="normal" font="default" size="100%">Bambang Purwanto</style></author><author><style face="normal" font="default" size="100%">Risky Vitria Prasetyo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of Magnesium Supplementation on Kidney Function and Phosphate Levels in Children with Chronic Kidney Disease and Hyperphosphatemia: A Double-blind Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Children</style></keyword><keyword><style  face="normal" font="default" size="100%">Chronic Kidney Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Hyperphosphatemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Kidney Function.</style></keyword><keyword><style  face="normal" font="default" size="100%">Magnesium</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">253-257</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Pediatric patients with chronic kidney disease (CKD) who have hyperphosphatemia may experience further deterioration in kidney function. This study aims to investigate the effect of magnesium supplementation on the reduction of phosphate levels and improvement of kidney function in children with CKD and hyperphosphatemia, compared to a placebo. &lt;strong&gt;Methods: &lt;/strong&gt;A randomized, double-blind, placebocontrolled trial was conducted at Pediatric Ward in our setting during March-July 2022. We compared oral magnesium supplementation (6 mg/kg body weight/day for two months) with a placebo in children with CKD and hyperphosphatemia (ages 1-18 years old). Patients who were on dialysis and had serum magnesium levels of &amp;lt;1.6 mg/dL and &amp;gt;2.4 mg/dL, and were allergic to magnesium supplementation were excluded. A paired T-test and the Wilcoxon signed-rank test were used for statistical analysis. &lt;strong&gt;Results:&lt;/strong&gt; We collected 31 children in the experimental group and 29 children in the placebo group. Phosphate levels were decreased in both the magnesium supplementation and placebo groups (5.4 ± 0.9 to 4.8 ± 1.1 mg/dL; &lt;em&gt;p&lt;/em&gt;-value = 0.001 and 5.1 ± 0.6 to 4.3 ± 1.2 mg/dL; &lt;em&gt;p&lt;/em&gt;-value=0.003). However, when compared between groups, the reductions were not significantly different (0.7 vs 0.8; &lt;em&gt;p&lt;/em&gt;-value=0.935). A significant improvement was found in kidney function in both groups using estimated Glomerular Filtration Rate (eGFR) (83.4±25.3 to 118.8±52; &lt;em&gt;p&lt;/em&gt;-value=&amp;lt;0.001 and 86.3±28.1 to 96.9 ± 35.8; p-value=0.004), and the reductions were significantly different (35.4 vs 10.7; &lt;em&gt;p&lt;/em&gt;-value=0.045).&lt;strong&gt; Conclusion: &lt;/strong&gt;Magnesium supplements have considerably lower phosphate levels and markedly improved kidney function in children with CKD and hyperphosphatemia.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">253</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Glabela Christiana Pandango&lt;sup&gt;1&lt;/sup&gt;, Bambang Purwanto&lt;sup&gt;2&lt;/sup&gt;, Risky Vitria Prasetyo&lt;sup&gt;1,*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Child Health, Faculty of Medicine Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Physiology, Faculty of Medicine Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ernyasih</style></author><author><style face="normal" font="default" size="100%">Anwar Mallongi</style></author><author><style face="normal" font="default" size="100%">Anwar Daud</style></author><author><style face="normal" font="default" size="100%">Sukri Palutturi</style></author><author><style face="normal" font="default" size="100%">Stang</style></author><author><style face="normal" font="default" size="100%">Razak Thaha</style></author><author><style face="normal" font="default" size="100%">Erniwaty Ibrahim</style></author><author><style face="normal" font="default" size="100%">Wesam Al Moudhun</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Model Prediction of Potential Disease Effects from PM2.5 Emission Among School Children in Coming 30 years in South Tangerang</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acute respiratory infection.</style></keyword><keyword><style  face="normal" font="default" size="100%">Children</style></keyword><keyword><style  face="normal" font="default" size="100%">Particulate matter</style></keyword><keyword><style  face="normal" font="default" size="100%">Transportation</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">400-404</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;The largest global environmental health risk factor is the ambient of air pollution, that largely attributed to transportation emissions. One of the main causes of PM&lt;sub&gt;2.5&lt;/sub&gt; emissions is thought to be onroad transportation. PM&lt;sub&gt;2.5 &lt;/sub&gt;has an impact on health, especially on children that relate to the respiratory system such as asthma, lung cancer, and decreased intelligence. &lt;strong&gt;Objective:&lt;/strong&gt; The research objective was to predict the risk potential disease due to PM2.5 in children from vehicle emissions in South Tangerang City. &lt;strong&gt;Method:&lt;/strong&gt; This research is an observational analytic study with a cross-sectional study design using a dynamic model approach using STELLA software. The environmental and human samples aare used to calculate the exposure level to PM&lt;sub&gt;2.5&lt;/sub&gt; taken from 32 points in 7 sub-districts of South Tangerang City (North Serpong, Serpong, Pondok Aren, Ciputat, East Ciputat, Pamulang, and Setu). then, meteorological data was also collected. &lt;strong&gt;Results:&lt;/strong&gt; The number of vehicles in the city of South Tangerang is quite high, especially between 11:00 and 15:00 with the majority of vehicles passing by are cars and motorbikes. PM&lt;sub&gt;2.5&lt;/sub&gt; pollution levels will fluctuate until 2053. The effects of temperature, weather, and humidity might cause an increase in PM&lt;sub&gt;2.5&lt;/sub&gt; pollutants at specific times. According to the modeling calculation results, even though there are occasions when PM&lt;sub&gt;2.5&lt;/sub&gt; pollution levels fall, acute respiratory infection (ARI) incidence in children will continue to rise over time. Although PM&lt;sub&gt;2.5 &lt;/sub&gt;emissions fluctuate, exposure to PM&lt;sub&gt;2.5&lt;/sub&gt; in low concentrations poses a risk to human health.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">400</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Ernyasih&lt;sup&gt;1&lt;/sup&gt;, Anwar Mallongi&lt;sup&gt;2,*&lt;/sup&gt;, Anwar Daud&lt;sup&gt;2&lt;/sup&gt;, Sukri Palutturi&lt;sup&gt;3&lt;/sup&gt;, Stang&lt;sup&gt;4&lt;/sup&gt;, Razak Thaha&lt;sup&gt;5&lt;/sup&gt;, Erniwaty Ibrahim&lt;sup&gt;2&lt;/sup&gt;, Wesam Al Moudhun&lt;sup&gt;6&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Postgraduate Program, Faculty of Public Health, Hasanuddin University, Faculty of Public Health, Universitas Muhammadiyah Jakarta, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Environmental Health Department, Faculty of Public Health, Hasanuddin University, Makassar, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Health Policy and Administration, Faculty of Public Health, Hasanuddin University, Makassar, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Biostatistics and Population, Faculty of Public Health, Hasanuddin University, Makassar, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;5&lt;/sup&gt;Community Nutrition Study Program, Faculty of Public Health, Hasanuddin University, Makassar, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;6&lt;/sup&gt;Environmnetal Health Department, Faculty of Public Health, Gaza University, PALESTINE.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agniya Ali Fahmi Hikmat</style></author><author><style face="normal" font="default" size="100%">Mia Ratwita Andarsini</style></author><author><style face="normal" font="default" size="100%">Bagus Setyoboedi</style></author><author><style face="normal" font="default" size="100%">Maria Christina Shanty Larasati</style></author><author><style face="normal" font="default" size="100%">Andi Cahyadi</style></author><author><style face="normal" font="default" size="100%">I Dewa Gede Ugrasena</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Risk Factors for Hepatotoxicity From L-Asparaginase Chemotherapy In Children With Acute Lymphoblastic Leukemia</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acute lymphoblastic leukemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Children</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatotoxicity</style></keyword><keyword><style  face="normal" font="default" size="100%">L-asparaginase</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">January 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">921-927</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; L-asparaginase chemotherapy often causes hepatotoxicity and affects complete remission in pediatric acute lymphoblastic leukemia (ALL). This study aims to investigate the risk factors that affect the incidence of hepatotoxicity caused by L-asparaginase chemotherapy in ALL children. &lt;strong&gt;Methods:&lt;/strong&gt; An observational study with prospective sampling was conducted at Dr. Soetomo Hospital, Surabaya. The inclusion criteria included ALL children aged 1-18 years, undergoing ALL Induction phase chemotherapy based on the 2018 Indonesian Children's ALL protocol as evidenced by bone marrow aspiration, receiving L-asparaginase chemotherapy, and obtaining written consent from parents or guardians. Each child had 3 ml of blood drawn from a peripheral vein to assess their complete blood count, alanine transaminase (ALT) levels, and albumin level. &lt;strong&gt;Results:&lt;/strong&gt; Thirty-two children with ALL were collected. Two of them were excluded due to allergic reaction and enable to continue the L-asparaginase chemotherapy. Thirty of them were eligible participants. Approximately 53.3% of ALL children aged ≤ seven years. Fourteen (47%) children with ALL were included in the standard-risk group and 16 (53%) of them included high-risk group. There were significant differences in ALT levels between the four stages of observation (p=&amp;lt;0.001). Twenty-two ALL children had hepatotoxicity (73.3%), while 8 had non-hepatotoxicity (26.7%). Two risk factors had a significant influence on the occurrence of hepatotoxicity due to L-asparaginase chemotherapy including age and hypoalbuminemia (p=0.045, p=0.028). &lt;strong&gt;Conclusion:&lt;/strong&gt; Age and hypoalbuminemia were the risk factors that might affect the incidents of hepatotoxicity. Clinical monitoring before and after treatment needs to be done to prevent poor outcomes.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">921</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Agniya Ali Fahmi Hikmat&lt;sup&gt;1&lt;/sup&gt;, Mia Ratwita Andarsini&lt;sup&gt;1,2,*&lt;/sup&gt;, Bagus Setyoboedi&lt;sup&gt;1,2&lt;/sup&gt;, Maria Christina Shanty Larasati&lt;sup&gt;1,2&lt;/sup&gt;, Andi Cahyadi&lt;sup&gt;1,2&lt;/sup&gt;, I Dewa Gede Ugrasena&lt;sup&gt;1,2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Child Health, Faculty of Medicine Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Dr. Soetomo General Academic Teaching Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>